These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22031823)

  • 1. Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease.
    Sibley CR; Wood MJ
    PLoS One; 2011; 6(10):e26194. PubMed ID: 22031823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.
    de Yñigo-Mojado L; Martín-Ruíz I; Sutherland JD
    PLoS One; 2011; 6(6):e21352. PubMed ID: 21712955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
    Covy JP; Giasson BI
    Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients.
    Vishwanathan Padmaja M; Jayaraman M; Srinivasan AV; Srikumari Srisailapathy CR; Ramesh A
    Parkinsonism Relat Disord; 2012 Jul; 18(6):801-2. PubMed ID: 22436655
    [No Abstract]   [Full Text] [Related]  

  • 10. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at onset in LRRK2-associated PD is modified by SNCA variants.
    Botta-Orfila T; Ezquerra M; Pastor P; Fernández-Santiago R; Pont-Sunyer C; Compta Y; Lorenzo-Betancor O; Samaranch L; Martí MJ; Valldeoriola F; Calopa M; Fernández M; Aguilar M; de Fabregas O; Hernández-Vara J; Tolosa E
    J Mol Neurosci; 2012 Sep; 48(1):245-7. PubMed ID: 22669510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Parkinson's disease using induced pluripotent stem cells.
    Byers B; Lee HL; Reijo Pera R
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
    Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
    Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
    Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
    Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
    Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease.
    Squillaro T; Cambi F; Ciacci G; Rossi S; Ulivelli M; Malandrini A; Mencarelli MA; Mari F; Renieri A; Ariani F
    J Hum Genet; 2007; 52(3):201-204. PubMed ID: 17235449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
    Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
    Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.